Your browser is no longer supported. Please, upgrade your browser.
Prothena Corporation plc
Index- P/E- EPS (ttm)-2.56 Insider Own0.05% Shs Outstand39.92M Perf Week6.01%
Market Cap536.13M Forward P/E- EPS next Y-1.35 Insider Trans0.00% Shs Float39.90M Perf Month0.97%
Income-102.00M PEG- EPS next Q-0.74 Inst Own94.90% Short Float3.61% Perf Quarter18.69%
Sales0.70M P/S765.89 EPS this Y50.50% Inst Trans0.19% Short Ratio5.41 Perf Half Y3.82%
Book/sh5.25 P/B2.59 EPS next Y51.10% ROA-26.30% Target Price19.17 Perf Year-11.64%
Cash/sh7.97 P/C1.70 EPS next 5Y-8.40% ROE-42.00% 52W Range7.10 - 15.90 Perf YTD13.16%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-31.50% 52W High-14.53% Beta1.53
Dividend %- Quick Ratio14.80 Sales past 5Y-56.30% Gross Margin- 52W Low91.41% ATR0.70
Employees51 Current Ratio14.80 Sales Q/Q0.00% Oper. Margin- RSI (14)58.67 Volatility5.65% 4.81%
OptionableYes Debt/Eq0.00 EPS Q/Q-57.10% Profit Margin- Rel Volume0.76 Prev Close14.40
ShortableYes LT Debt/Eq0.00 EarningsNov 04 AMC Payout- Avg Volume266.08K Price13.59
Recom2.50 SMA204.71% SMA5010.04% SMA20015.95% Volume202,400 Change-5.62%
Dec-07-20Initiated H.C. Wainwright Buy $22
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Mar-02-17Initiated Instinet Buy $87
Dec-21-16Initiated SunTrust Buy $75
Nov-03-16Initiated Deutsche Bank Buy $73
Aug-04-16Reiterated Barclays Overweight $60 → $70
May-13-16Initiated Barclays Overweight $60
Feb-19-16Reiterated Wedbush Outperform $81 → $77
Jan-21-16Initiated Credit Suisse Outperform
Dec-09-20 08:00AM  
Dec-04-20 04:05PM  
Nov-27-20 12:25AM  
Nov-16-20 02:56AM  
Nov-05-20 11:13AM  
Nov-04-20 06:35PM  
Oct-28-20 04:05PM  
Oct-21-20 10:48AM  
Oct-20-20 04:05PM  
Oct-02-20 04:05PM  
Sep-29-20 02:35PM  
Sep-15-20 08:30AM  
Sep-11-20 08:30AM  
Sep-08-20 04:05PM  
Sep-05-20 11:31AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-06-20 08:10PM  
Aug-05-20 04:05PM  
Aug-03-20 12:09PM  
Jul-30-20 04:05PM  
Jul-28-20 12:33PM  
Jul-10-20 08:34AM  
Jun-19-20 12:47PM  
May-27-20 04:05PM  
May-18-20 07:26AM  
May-06-20 07:45PM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-24-20 04:30PM  
Apr-22-20 09:15AM  
Apr-21-20 10:20AM  
Apr-03-20 04:05PM  
Mar-31-20 04:05PM  
Mar-13-20 11:30AM  
Mar-03-20 04:05PM  
Feb-17-20 06:31PM  
Feb-13-20 10:45AM  
Feb-12-20 05:35PM  
Feb-05-20 04:05PM  
Jan-20-20 11:21AM  
Dec-30-19 08:35AM  
Dec-11-19 03:47PM  
Dec-05-19 04:05PM  
Nov-19-19 11:03AM  
Nov-06-19 03:14PM  
Nov-05-19 06:55PM  
Oct-29-19 04:05PM  
Oct-15-19 01:49AM  
Oct-07-19 09:00AM  
Sep-20-19 01:04PM  
Sep-11-19 01:39PM  
Sep-05-19 09:31AM  
Aug-06-19 07:25PM  
Jul-30-19 04:05PM  
Jul-05-19 04:39PM  
Jul-03-19 03:26PM  
Jul-01-19 04:05PM  
Jun-06-19 09:31AM  
May-30-19 04:05PM  
May-11-19 01:28PM  
May-08-19 08:51AM  
May-07-19 06:55PM  
Apr-30-19 04:05PM  
Apr-18-19 04:05PM  
Apr-04-19 12:12PM  
Mar-26-19 04:25PM  
Mar-16-19 09:30AM  
Mar-15-19 06:48PM  
Mar-14-19 05:15PM  
Mar-12-19 11:11AM  
Mar-05-19 04:05PM  
Mar-01-19 06:29AM  
Feb-15-19 02:03PM  
Feb-14-19 05:50PM  
Feb-07-19 10:31AM  
Feb-04-19 04:05PM  
Jan-30-19 08:15AM  
Dec-20-18 06:04AM  
Dec-10-18 08:38AM  
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kinney Gene G.President and CEOAug 17Option Exercise6.4110,00064,10012,793Aug 19 04:31 PM